Δ
Race-Develops-Improved-IV-Formulation-of-ZantreneDownload To discuss or comment on this announcement please visit our Investor Hub.
Race Oncology (“Race”) is pleased to announce that it has been issued a new patent…
United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE…